Selective cytotoxicity of the anti-diabetic drug, metformin, in glucose-deprived chicken DT40 cells.
Kei KadodaTakahito MoriwakiMasataka TsudaHiroyuki SasanumaMasamichi IshiaiMinoru TakataHiroshi IdeShin-Ichiro MasunagaShunichi TakedaKeizo TanoPublished in: PloS one (2017)
Metformin is a biguanide drug that is widely used in the treatment of diabetes. Epidemiological studies have indicated that metformin exhibits anti-cancer activity. However, the molecular mechanisms underlying this activity currently remain unclear. We hypothesized that metformin is cytotoxic in a tumor-specific environment such as glucose deprivation and/or low oxygen (O2) tension. We herein demonstrated that metformin was highly cytotoxic under glucose-depleted, but not hypoxic (2% O2) conditions. In order to elucidate the underlying mechanisms of this selective cytotoxicity, we treated exposed DNA repair-deficient chicken DT40 cells with metformin under glucose-depleted conditions and measured cellular sensitivity. Under glucose-depleted conditions, metformin specifically killed fancc and fancl cells that were deficient in FANCC and FANCL proteins, respectively, which are involved in DNA interstrand cross-link repair. An analysis of chromosomal aberrations in mitotic chromosome spreads revealed that a clinically relevant concentration of metformin induced DNA double-strand breaks (DSBs) in fancc and fancl cells under glucose-depleted conditions. In summary, metformin induced DNA damage under glucose-depleted conditions and selectively killed cells. This metformin-mediated selective toxicity may suppress the growth of malignant tumors that are intrinsically deprived of glucose.
Keyphrases
- induced apoptosis
- dna damage
- cell cycle arrest
- blood glucose
- dna repair
- oxidative stress
- type diabetes
- cardiovascular disease
- gene expression
- signaling pathway
- copy number
- single cell
- adipose tissue
- diabetic rats
- metabolic syndrome
- cell free
- skeletal muscle
- genome wide
- glycemic control
- electronic health record
- endothelial cells
- replacement therapy
- dna damage response